Larimar Therapeutics Inc
Follow $LRMR
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $LRMR by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredsnapshot unavailable for LRMR. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is LRMR moving today?
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
LRMR overview
Related filings and maps
Congress activity in LRMR
No receipt-qualified filings found.
LRMR contract awards, year to date.
Public federal awards linked to this ticker.
LRMR lobbying filings, year to date.
Registered lobbying filings matched to Larimar Therapeutics Inc.